Drug-Pricing “Experts” And CBO Underestimate The Threat To Innovation

The Congressional Budget Office and academic researchers ignore or misunderstand small companies when they analyze the impact of proposed price controls with potentially devastating consequences for new drug development. Polls show that 65% of voters would oppose the legislation to lower drug prices if it reduced the supply of new drugs. To reassure the public, proponents rely on “experts”, who lack the theoretical tools needed for proper analysis.

Read the source article at forbes.com
2021-09-30 01:00:00